OP
hVIVO plc
OPORF · OTC
$0.11 +0.00% (+$0.00)
Market Cap £56.5M
P/E Ratio -
Div. Yield -
ROE 14.53%
Bulios Fair Price
$0.12
9.5% upside
Current Price
$0.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OPORF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
75 /100
Cheap P/S 1.21x
P/B 1.48x
EV/EBITDA 13.23x
Growth
28 /100
Declining Book val. growth 23.57%
Rev. growth 2.65%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 31.64%
Op. margin 0.75%
Gross margin 13.09%
Quality
8 /100
Poor Asset turnover 0.65x
ROA 8.35%
ROIC 2.28%
Debt
75 /100
Low Net debt/EBITDA 0.11x
Int. coverage -0.29x
Debt/Equity 0.39x
Stability
21 /100
Unstable Profitable years 0
EPS volatility 1,244.77%
Beta 1.71x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OPORF
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Yamin Mohammed Khan
Employees
376
Headquarters
London
Upcoming events
14 APR
Earnings
Upcoming earnings report